

# Small Molecules

## TTNPB

Retinoid pathway activator; Activates retinoic acid receptor (RAR)

Catalog # 72892

10 mg



Scientists Helping Scientists™ | WWW.STEMCELL.COM

TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713


INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM

FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

## Product Description

TTNPB is an analog of retinoic acid that potently and selectively activates retinoic acid receptors (RAR; EC<sub>50</sub> = 21, 4, and 2.4 nM for RAR $\alpha$ , RAR $\beta$ , and RAR $\gamma$ , respectively; Beard et al.; Wong et al.). It does not act on retinoid X receptors and weakly agonizes farnesoid X receptor (EC<sub>50</sub> > 1  $\mu$ M; Maloney et al.; Wong et al.). TTNPB is used to study RAR action in diverse processes, including epidermal cell proliferation, embryogenesis, and stem cell differentiation (Araoka et al.; Hou et al.; Minucci et al.; Thacher et al.).

Molecular Name:	TTNPB
Alternative Names:	AGN 191183; Arotinoid Acid; Ro 13-7410
CAS Number:	71441-28-6
Chemical Formula:	C <sub>24</sub> H <sub>28</sub> O <sub>2</sub>
Molecular Weight:	348.5 g/mol
Purity:	≥ 98%
Chemical Name:	4-[(1E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propen-1-yl]-benzoic acid
Structure:	



## Properties

Physical Appearance:	A crystalline solid
Storage:	Product stable at -20°C as supplied. Protect from prolonged exposure to light. Stable as supplied for 12 months from date of receipt.
Solubility:	· Absolute ethanol ≤ 280 $\mu$ M · DMSO ≤ 5.7 mM For example, to prepare a 1 mM stock solution in DMSO, resuspend 1 mg in 2.86 mL of fresh DMSO.

Prepare stock solution fresh before use. Information regarding stability of small molecules in solution has rarely been reported, however, as a general guide we recommend storage in DMSO at -20°C. Aliquot into working volumes to avoid repeated freeze-thaw cycles. The effect of storage of stock solution on compound performance should be tested for each application.

Compound has low solubility in aqueous media. For use as a cell culture supplement, stock solution should be diluted into culture medium immediately before use. Avoid final DMSO concentration above 0.1% due to potential cell toxicity.

## Published Applications

### REPROGRAMMING

- Enables chemical reprogramming (without genetic factors) of mouse embryonic fibroblasts to induced pluripotent stem cells, in combination with CHIR99021 (Catalog #72052), Tranylcypromine (72272), Valproic Acid (Catalog #72292), 3-Deazaneplanocin A (Catalog #72322), and RepSox (Catalog #73792) (Hou et al.).

### DIFFERENTIATION

- In combination with CHIR99021 or Activin A (Catalog #78001), induces intermediate mesoderm formation from human or mouse pluripotent stem cells, respectively (Araoka et al.; Oeda et al.).
- Promotes neuronal differentiation in cultured chick caudal neural plate explants (Diez del Corral et al.).

### CANCER RESEARCH

- Induces the in vitro growth and differentiation to granulocytes of myeloid progenitor cells isolated from myelodysplastic syndrome (MDS) patients (Fabian et al.).

## References

- Araoka T et al. (2014) Efficient and rapid induction of human iPSCs/ESCs into nephrogenic intermediate mesoderm using small molecule-based differentiation methods. *PLoS One* 9(1): e84881.
- Beard RL et al. (1995) Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids. *J Med Chem* 38(15): 2820–9.
- Diez del Corral R et al. (2003) Opposing FGF and retinoid pathways control ventral neural pattern, neuronal differentiation, and segmentation during body axis extension. *Neuron* 40(1): 65–79.
- Fabian I et al. (1987) In-vitro growth and differentiation of marrow cells from myelodysplastic patients in the presence of a retinoid benzoic acid derivative. *Leuk Res* 11(7): 635–40.
- Hou P et al. (2013) Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. *Science* 341(6146): 651–4.
- Maloney PR et al. (2000) Identification of a chemical tool for the orphan nuclear receptor FXR. *J Med Chem* 43(16): 2971–4.
- Minucci S et al. (1996) Retinoid X receptor-selective ligands produce malformations in *Xenopus* embryos. *Proc Natl Acad Sci USA* 93(5): 1803–7.
- Oeda S et al. (2013) Induction of intermediate mesoderm by retinoic acid receptor signaling from differentiating mouse embryonic stem cells. *Int J Dev Biol* 57(5): 383–9.
- Thacher SM et al. (1997) Receptor specificity of retinoid-induced epidermal hyperplasia: effect of RXR-selective agonists and correlation with topical irritation. *J Pharmacol Exp Ther* 282(2): 528–34.
- Wong MF et al. (1997) Synthesis and receptor binding affinity of conformationally restricted retinoic acid analogues. *Bioorg Med Chem Lett* 7(17): 2313–8.

## Related Small Molecules

For a complete list of small molecules available from STEMCELL Technologies, visit [www.stemcell.com/smallmolecules](http://www.stemcell.com/smallmolecules) or contact us at [techsupport@stemcell.com](mailto:techsupport@stemcell.com).

**This product is hazardous. Please refer to the Safety Data Sheet (SDS).**

STEMCELL TECHNOLOGIES INC.'S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2017 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design, and Scientists Helping Scientists are trademarks of STEMCELL Technologies Canada Inc. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.